(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/005635 A3

(51) International Patent Classification[7]: C12N 15/13, 5/16, A61K 39/395

(21) International Application Number: PCT/EP2004/007562

(22) International Filing Date: 9 July 2004 (09.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03015526.1 10 July 2003 (10.07.2003) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GRAUS, Yvo** [NL/NL]; Pienemanstraat 112, NL-6717 WG Ede (NL). **KOPETZKI, Erhard** [DE/DE]; Kastnerhofstr. 21, 82377 Penzberg (DE). **KUENKELE, Klaus-Peter** [DE/DE]; Karwendelstrasse 9, 83671 Benediktbeuern (DE). **MUNDIGL, Olaf** [DE/DE]; Tassiloring 16, 82362 Weilheim (DE). **PARREN, Paul** [NL/NL]; Werdorperwaard 17, NL-3984 PR Odijk (NL). **REBERS, Frank** [NL/NL]; Adriaan Menninckkwartier 34, NL-3554 CT Utrecht (NL). **SCHUMACHER, Ralf** [DE/DE]; Hochfeldstrasse 78, 82377 Penzberg (DE). **VAN DE WINKEL, Jan** [NL/NL]; Verlengde Slotlaan 80, NL-3707 CK Zeist (NL). **VRIESEMA-VAN VUGT, Martine** [NL/NL]; Fluweelmos 6, NL-3994 KR Houten (NL).

(74) Agent: **SCHREINER, Siegfried**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

(88) Date of publication of the international search report: 25 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF

(57) Abstract: An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IGF-IR which is characterized in that said antibody is a) is ofIgG1 isotype, b) shows a ratio of IC_{50} values of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IG-II to IGF-IR of 1:3 to 3:1, c) inhibits for at least 80% at a concentration of 5 nM IGF-IR phospohrylation in a cellular phosphorylation assay using 3T3 cells providing 400,000 to 600,000 molecules IGF-IR per cell in a medium containing 0.5% heat inactivated fetal calf serum (FCS) when compared to such an assay without said antibody, and d) shows no IGF-IR stimulating activity measured as IGF-IR phophorylation at a concentration of 10 μM in a cellular phosphorylation assay using 3T3 providing 400,000 to 600,000 molecules IGF-IR per cell in a medium containing 0,5% heat inactivated fetal calf serum (FCS) when compared to such an assay without said antibody has improved properties in antitumor therapy.

WO 2005/005635 A3